# Hyperactive Catatonia in an Adolescent With Prader-Willi Syndrome

**Authors:** Rame Alharbi, Saeed S Shaaban, Eric MacMaster

PMC · DOI: 10.7759/cureus.82304 · Cureus · 2025-04-15

## TL;DR

This paper reports a case of hyperactive catatonia in a teenager with Prader-Willi syndrome and highlights the successful use of lorazepam for treatment.

## Contribution

The paper adds to the limited literature on catatonia in pediatric Prader-Willi syndrome and demonstrates lorazepam's effectiveness.

## Key findings

- The patient exhibited hyperactive catatonia with motor symptoms progressing to psychotic features.
- Lorazepam was consistently effective in treating the catatonia during hospitalization.
- The case underscores the need for more research on catatonia in Prader-Willi syndrome.

## Abstract

Catatonia, a neuropsychiatric syndrome, has been increasingly recognized as a possible complication of Prader-Willi syndrome (PWS). There is limited research surrounding catatonia and its sequelae in PWS. Given the scarcity and severity of catatonia in pediatric age, there is a need to expand on the available literature. We present a case of hyperactive catatonia in an adolescent with PWS. After obtaining a thorough history, we followed her progression from motor symptoms to developing psychotic features. Although her presentation required multiple doses of lorazepam, it was shown to be consistently effective in treating her catatonia during her hospital stay.

## Linked entities

- **Chemicals:** lorazepam (PubChem CID 3958)
- **Diseases:** Prader-Willi syndrome (MONDO:0008300), catatonia (MONDO:0800105)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** cognitive deficits (MESH:D003072), schizophrenia (MESH:D012559), echolalia (MESH:D004454), developmental delay (MESH:D002658), PWS (MESH:D011218), Catatonia (MESH:D002389), behavioral dysregulation (MESH:D021081), catatonic (MESH:D012560), autonomic abnormalities (MESH:D009461), narcolepsy (MESH:D009290), paranoia (MESH:D010259), dyskinetic (MESH:D002547), growth restriction (MESH:D005317), neuropsychiatric conditions (MESH:D001523), hoarseness (MESH:D006685), stupor (MESH:D053608), microcephaly (MESH:D008831), neuropsychiatric syndrome (MESH:C000631768), paranoid behavior (MESH:D010260), UPD (MESH:D024182), hypotonia (MESH:D009123), Anaplasma (MESH:D000712), psychotic features (MESH:D019967), psychosis (MESH:D011618), genetic abnormalities (MESH:D030342), delusions of grandeur (MESH:D063726), stroke (MESH:D020521), metabolic disturbances (MESH:D024821), abnormal movements (MESH:D004409), neoplasms (MESH:D009369), infection (MESH:D007239), agitation (MESH:D011595), depressive episodes (MESH:D003866), bipolar disorder (MESH:D001714), autism (MESH:D001321), hyperphagia (MESH:D006963), autoimmune diseases (MESH:D001327), visual hallucinations (MESH:D006212), Lyme disease (MESH:D008193)
- **Chemicals:** lorazepam (MESH:D008140), GABA (MESH:D005680), somatropin (MESH:D019382), risperidone (MESH:D018967), midazolam (MESH:D008874), benzodiazepines (MESH:D001569), haloperidol (MESH:D006220), pitolisant (MESH:C516975)
- **Species:** Homo sapiens (human, species) [taxon 9606], Babesia (genus) [taxon 5864]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12081129/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12081129/full.md

---
Source: https://tomesphere.com/paper/PMC12081129